Cryptococcal infections: Changing epidemiology and implications for therapy

Drugs

Volumn 73, Issue 6, 2013, Pages 495-504

  La Hoz, Ricardo M ^a   Pappas, Peter G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; BACTERIAL ANTIGEN; CALCINEURIN INHIBITOR; FLUCONAZOLE; FLUCYTOSINE; GAMMA1B INTERFERON;

AFRICA SOUTH OF THE SAHARA; ANTIGEN DETECTION; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; CANADA; COST CONTROL; CRYPTOCOCCOSIS; DRUG MEGADOSE; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RATE; LATEX AGGLUTINATION TEST; LIVER CIRRHOSIS; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MICROSCOPY; MONOTHERAPY; MORTALITY; ORGAN TRANSPLANTATION; PANDEMIC; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID ORGAN TRANSPLANTATION; SOUTH AFRICA; TREATMENT DURATION;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; GRAFT REJECTION; HIV INFECTIONS; HUMANS;

CRYPTOCOCCUS GATTII;

EID: 84878322313     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0037-z     Document Type: Review

References (89)

1. Baddley JW, Dismukes WE. Cryptococcosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukers WE, editors. Essentials of clinical mycology. 2nd ed. New York: Springer; 2011. p. 207-26.
2. R Ikeda T Shinoda Y Fukuzawa, et al. 1982 Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates J Clin Microbiol 36 22 29
3. Kwon-Chung KJ, Boekhout T, Fell JW, et al. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Trenomellomycetidae). Taxon. 2002;51:804-086.
4. SP Franzot IF Salkin A Casadevall 1999 Cryptococcus neoformans var. Grubii: Separate varietal status for Cryptococcus neoformans serotype a isolates J Clin Microbiol 37 838 840 9986871 1:STN:280:DyaK1M7ktlaluw%3D%3D
5. F Sanfelice 1894 Contributo alle morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti Ann Isto Igiene R Univ Roma 4 463 495
6. F Dromer S Mathoulin-Pelissier A Fontanet O Ronin B Dupont O Lortholary French Cryptococcosis Study G 2004 Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre and post-HAART eras AIDS 18 555 562 15090810 10.1097/00002030-200402200-00024
7. JE Kaplan D Hanson MS Dworkin T Frederick J Bertolli ML Lindegren, et al. 2000 Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy Clin Infect Dis 30 Suppl 1 S5 S14 10770911 10.1086/313843
8. SA Mirza M Phelan D Rimland E Graviss R Hamill ME Brandt, et al. 2003 The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000 Clin Infect Dis 36 789 794 12627365 10.1086/368091
9. LJ van Elden AM Walenkamp MM Lipovsky P Reiss JF Meis S de Marie, et al. 2000 Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy AIDS 14 2787 2788 11125898 10.1097/00002030-200012010-00019
10. BJ Park KA Wannemuehler BJ Marston, et al. 2009 Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS AIDS 23 4 525 530 19182676 10.1097/QAD.0b013e328322ffac
11. SD Lawn AD Harries X Anglaret, et al. 2008 Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa AIDS 22 15 1897 1908 18784453 10.1097/QAD.0b013e32830007cd
12. D Mabey RW Peeling A Ustianowski MD Perkins 2004 Diagnostics for the developing world Nat Rev Microbiol 2 231 240 15083158 10.1038/nrmicro841 1:CAS:528:DC%2BD2cXhsVWgur0%3D
13. WHO. Mapping the landscape of diagnostics for sexually transmitted infections. Key findings and recommendations. UNICEF/UNDP/World Bank/WHO, 2004.
14. MD Lindsley N Mekha HC Baggett, et al. 2011 Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis Clin Infect Dis 53 4 321 325 21810743 10.1093/cid/cir379
15. JN Jarvis A Percival S Bauman, et al. 2011 Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis Clin Infect Dis 53 10 1019 1023 21940419 10.1093/cid/cir613 1:CAS:528:DC%2BC3MXhtlejsb3P
16. Binnicker MJ, Jespersen DJ, Bestrom JE, et al. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1988-90.
17. JN Jarvis G Meintjes R Wood, et al. 2010 Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme AIDS 24 8 1233 1235 20421745 10.1097/QAD.0b013e3283383aeb
18. M Roy T Chiller 2011 Preventing deaths from cryptococcal meningitis: from bench to bedside Expert Rev Anti Infect Ther 9 9 715 717 21905781 10.1586/eri.11.86
19. R Micol O Lortholary B Sar, et al. 2007 Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients J Acquir Immune Defi c Syndr 45 555 559 10.1097/QAI.0b013e31811ed32c
20. JN Jarvis SD Lawn M Vogt N Bangani R Wood TS Harrison 2009 Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa Clin Infect Dis 48 856 862 19222372 10.1086/597262 1:CAS:528:DC%2BD1MXksFalsL8%3D
21. DB Meya YC Manabe B Castelnuovo, et al. 2010 Cost-eff ectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 + cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings Clin Infect Dis 51 448 455 20597693 10.1086/655143
22. R Rajasingham DB Meya DR Boulware 2012 Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care J Acquir Immune Defic Syndr 59 5 e85 e91 22410867 10.1097/QAI.0b013e31824c837e 1:CAS:528: DC%2BC38XjvVSksr4%3D
23. JN Jarvis SD Lawn R Wood, et al. 2010 Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action Clin Infect Dis 51 12 1463 1465 21082878 10.1086/657405
24. Jarvis JN, Govender N, Chiller T, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic). 2012;11(6):374-9.
25. Rajasingham R, Boulware DR. Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL. Clin Infect Dis. 2012;55(12):1742-4.
26. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev. 2005;3:CD004773.
27. R Parkes-Ratanshi K Wakeham J Levin, et al. 2011 Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Lancet Infect Dis 11 12 933 941 21982529 10.1016/S1473-3099(11)70245-6 1:CAS:528:DC%2BC3MXhsFGjt7bJ
28. JR Perfect WE Dismukes F Dromer, et al. 2010 Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america Clin Infect Dis 50 3 291 322 20047480 10.1086/649858
29. World Health Organization (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization. Available: http://whqlibdoc.who. int/publications/2011/9789241502979-eng.pdf. Accessed 2 Nov 2012.
30. CM van der Horst MS Saag GA Cloud, et al. 1997 Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group N Engl J Med 337 15 21 9203426 10.1056/NEJM199707033370103
31. AE Brouwer A Rajanuwong W Chierakul, et al. 2004 Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial Lancet 363 1764 1767 15172774 10.1016/S0140-6736(04)16301-0 1:CAS:528: DC%2BD2cXksVanu7s%3D
32. T Bicanic C Muzoora AE Brouwer, et al. 2009 Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients Clin Infect Dis 49 702 709 19613840 10.1086/604716 1:CAS:528:DC%2BD1MXhtFOju7bP
33. F Dromer C Bernede-Bauduin D Guillemot O Lortholary 2008 Major role for amphotericin B-flucytosine combination in severe cryptococcosis PLoS ONE 3 1 9 10.1371/journal.pone.0002870
34. Day JN, Chau TTH, Dung NT, Mai PP, Phu NH, et al. (2011) Combination antifungal therapy for HIV associated cryptococcal meningitis [abstract]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2011; Chicago, IL, United States.
35. PG Pappas P Chetchotisakd RA Larsen, et al. 2009 A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis Clin Infect Dis 48 12 1775 1783 19441980 10.1086/599112 1:CAS:528:DC%2BD1MXot12rt7s%3D
36. A Loyse D Wilson G Meintjes, et al. 2012 Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis Clin Infect Dis 54 1 121 128 22052885 10.1093/cid/cir745 1:CAS:528:DC%2BC3MXhs12gsr%2FE
37. S Shoham C Cover N Donegan, et al. 2005 Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease Clin Infect Dis 40 477 479 15668874 10.1086/427213
38. PG Pappas 2005 Managing cryptococcal meningitis is about handling the pressure Clin Infect Dis 40 480 482 15668875 10.1086/429329
39. PG Pappas B Bustamante E Ticona, et al. 2004 Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis J Infect Dis 189 12 2185 2191 15181565 10.1086/420829 1:CAS:528: DC%2BD2cXls1Shu70%3D
40. JN Jarvis G Meintjes K Rebe, et al. 2012 Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial AIDS 26 9 1105 1113 22421244 10.1097/QAD. 0b013e3283536a93 1:CAS:528:DC%2BC38Xnt12qur0%3D
41. CK Muzoora T Kabanda G Ortu, et al. 2012 Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis J Infect 64 1 76 81 22079502 10.1016/j.jinf.2011.10.014
42. JC Nussbaum A Jackson D Namarika, et al. 2010 Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi Clin Infect Dis 50 3 338 344 20038244 10.1086/649861 1:CAS:528:DC%2BC3cXislSqtrc%3D
43. R Rajasingham MA Rolfes KE Birkenkamp DB Meya DR Boulware 2012 Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis PLoS Med 9 9 e1001316 10.1371/journal.pmed.1001316 23055838 10.1371/journal.pmed.1001316
44. AR Zolopa J Andersen L Komarow, et al. 2009 Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial PLoS ONE 4 1 10 10.1371/journal.pone.0005575
45. AT Makadzange CE Ndhlovu K Takarinda, et al. 2010 Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa Clin Infect Dis 50 11 1532 1538 20415574 10.1086/652652 1:CAS:528:DC%2BC3cXnvVahsb8%3D
46. Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013;56(8):1165-73.
47. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant. 2012;12 (Suppl 1):1-156.
48. N Singh S Husain M De Vera, et al. 2004 Cryptococcus neoformans infection in patients with cirrhosis. Including liver transplant candidates Medicine (Baltimore) 83 3 188 192 10.1097/01.md.0000126760.45299.69
49. CD Sifri HY Sun TV Cacciarelli, et al. 2010 Pretransplant cryptococcosis and outcome after liver transplantation Liver Transpl 16 4 499 502 20373460
50. N Singh I How 2012 Treat cryptococcosis in organ transplant recipients Transplantation 93 1 17 21 22015465 10.1097/TP.0b013e318236cd1a
51. PA Grossi JA Fishman AST Infectious Disease Community of Practice 2009 Donor-derived infections in solid organ transplant recipients Am J Transplant 9 Suppl 4 S19 S26 20070680 10.1111/j.1600-6143.2009.02889.x
52. PA Grossi AN Costa D Fehily, et al. 2012 Infections and organ transplantation: new challenges for prevention and treatment-a colloquium Transplantation 93 5 Suppl S4 S39 22374265 10.1097/TP.0b013e3182481347
53. JA Fishman MA Greenwald PA Grossi 2012 Transmission of infection with human allografts: essential considerations in donor screening Clin Infect Dis 55 5 720 727 22670038 10.1093/cid/cis519
54. HY Sun BD Alexander O Lortholary, et al. 2010 Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients Clin Infect Dis 51 9 1062 1069 20879857 10.1086/656584
55. JW Baddley DC Schain AA Gupte, et al. 2011 Transmission of Cryptococcus neoformans by organ transplantation Clin Infect Dis 52 4 e94 e98 21220771 10.1093/cid/ciq216
56. PG Pappas BD Alexander DR Andes, et al. 2010 Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Clin Infect Dis 50 8 1101 1111 20218876 10.1086/651262
57. N Singh G Forrest 2009 AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients Am J Transplant 9 Suppl 4 S192 S198 20070681 10.1111/j.1600-6143.2009.02911.x
58. N Singh O Lortholary BD Alexander, et al. 2005 Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection Transplantation 80 8 1033 1039 16278582 10.1097/01.tp.0000173774.74388.49
59. PG Pappas JR Perfect GA Cloud, et al. 2001 Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy Clin Infect Dis 33 5 690 699 11477526 10.1086/322597 1:STN:280: DC%2BD3MvktlemtA%3D%3D
60. S Kiertiburanakul S Wirojtananugoon R Pracharktam, et al. 2006 Cryptococcosis in human immunodeficiency virus-negative patients Int J Infect Dis 10 1 72 78 16288998 10.1016/j.ijid.2004.12.004
61. U Jongwutiwes S Sungkanuparph S Kiertiburanakul 2008 Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients Jpn J Infect Dis 61 2 111 115 18362398
62. C Yuchong C Fubin C Jianghan, et al. 2012 Cryptococcosis in China (1985-2010): review of cases from Chinese database Mycopathologia 173 5-6 329 335 21979866 10.1007/s11046-011-9471-1
63. Ecevit IZ, Clancy CJ, Schmalfuss IM, et al. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. 2006;42:1443-7.
64. SX Wu NR Guo XF Li, et al. 2011 Human pathogenic fungi in China-emerging trends from ongoing national survey for 1986, 1996, and 2006 Mycopathologia 171 6 387 393 21509517 10.1007/s11046-011-9398-6 1:STN:280:DC%2BC3MvnvVWqug%3D%3D
65. KD Brizendine JW Baddley PG Pappas 2011 Pulmonary cryptococcosis Semin Respir Crit Care Med 32 6 727 734 22167400 10.1055/s-0031-1295720
66. S Shaunak WA Schell JR Perfect 1989 Cryptococcal meningitis with normal cerebrospinal fluid J Infect Dis 160 5 912 2809269 10.1093/infdis/160.5.912 1:STN:280:DyaK3c%2FjvVKmug%3D%3D
67. KJ Kwon-Chung A Varma 2006 Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 6 4 574 587 16696653 10.1111/j.1567-1364.2006.00088.x 1:CAS:528:DC%2BD28XlsFWhtb8%3D
68. TC Sorrell SC Chen P Ruma, et al. 1996 Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting J Clin Microbiol 34 1253 1260 8727912 1:CAS:528:DyaK28XjtVWmtb4%3D
69. EJ Byrnes 3rd RJ Bildfell SA Frank, et al. 2009 Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States J Infect Dis 199 7 1081 1086 19220140 10.1086/597306
70. KJ Kwon-Chung I Polacheck JE Bennett 1982 Improvedm ediumf or separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C) J Clin Microbiol 15 535 537 7042750 1:STN:280:DyaL387ptVegsA%3D%3D
71. KJ Kwon-Chung JE Bennett 1984 High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions Zentralbl. Bakteriol. Mikrobiol Hyg A 257 213 218 6207684 1:STN:280:DyaL2M%2FhvV2lsw%3D%3D
72. KJ Kwon-Chung JE Bennett 1984 Epidemiologic differences between the two varieties of Cryptococcus neoformans Am J Epidemiol 120 1 123 130 6377880 1:STN:280:DyaL2c3ltlKqtQ%3D%3D
73. C Stephen S Lester W Black, et al. 2002 Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia Can Vet J 43 10 792 794 12395765
74. E Galanis L MacDougall 2010 Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007 Emerg Infect Dis 16 251 257 20113555 10.3201/eid1602.090900
75. L MacDougall SE Kidd E Galanis, et al. 2007 Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA Emerg Infect Dis 13 42 50 17370514 10.3201/eid1301.060827
76. Centers for Disease Control and Prevention (CDC) 2010 Emergence of Cryptococcus gattii-Pacific Northwest, 2004-2010 MMWR Morb Mortal Wkly Rep 59 865 868
77. JR Harris SR Lockhart E Debess, et al. 2011 Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen Clin Infect Dis 53 12 1188 1195 22016503 10.1093/cid/cir723 1:STN:280: DC%2BC3MbovVymuw%3D%3D
78. S Chen T Sorrell G Nimmo B Speed B Currie D Ellis D Marriott T Pfeiffer D Parr K Byth 2000 Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group Clin Infect Dis 31 499 508 10987712 10.1086/313992 1:STN:280:DC%2BD3M%2FksVSlsQ%3D%3D
79. DH Mitchell TC Sorrell AM Allworth CH Heath AR McGregor K Papanaoum MJ Richards T Gottlieb 1995 Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome Clin Infect Dis 20 611 616 7756484 10.1093/clinids/20.3.611 1:STN:280: DyaK2M3ns1Sltg%3D%3D
80. B Speed D Dunt 1995 Clinical and host differences between infections with the two varieties of Cryptococcus neoformans Clin Infect Dis 21 28 34 7578756 10.1093/clinids/21.1.28 1:STN:280:DyaK28%2FmsFKjug%3D%3D
81. L MacDougall M Fyfe M Romney M Starr E Galanis 2011 Risk factors for Cryptococcus gattii infection, British Columbia, Canada Emerg Infect Dis 17 193 199 21291588 10.3201/eid1702.101020
82. KA Marr 2011 Cryptococcus gattii: the tip of the iceberg Clin Infect Dis 53 12 1196 1198 22016500 10.1093/cid/cir738
83. JR Harris SR Lockhart T Chiller 2012 Letter re: Marr editorial Clin Infect Dis 54 7 1038 1039 22267717 10.1093/cid/cir1019 1:STN:280: DC%2BC383psFKnsw%3D%3D
84. GR Thompson 3rd NP Wiederhold AW Fothergill, et al. 2009 Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans Antimicrob Agents Chemother 53 1 309 311 18955539 10.1128/AAC.01216-08 1:CAS:528:DC%2BD1MXhs1Kktrs%3D
85. N Iqbal EE DeBess R Wohrle, et al. 2010 Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States J Clin Microbiol 48 2 539 544 20007380 10.1128/JCM.01505-09 1:CAS:528:DC%2BC3cXkt1Sjtb0%3D
86. F Hagen MT Illnait-Zaragozi KH Bartlett, et al. 2010 In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates Antimicrob Agents Chemother 54 12 5139 5145 20855729 10.1128/AAC.00746-10 1:CAS:528:DC%2BC3cXhsF2nu7bJ
87. HS Chong R Dagg R Malik, et al. 2010 In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype J Clin Microbiol 48 11 4115 4120 20844209 10.1128/JCM.01271-10
88. A Espinel-Ingroff A Chowdhary M Cuenca-Estrella, et al. 2012 Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine Antimicrob Agents Chemother 56 6 3107 3113 22391546 10.1128/AAC.06252-11 1:CAS:528:DC%2BC38XnslWrt7c%3D
89. L Trilles W Meyer B Wanke, et al. 2012 Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex Med Mycol 50 3 328 332 21859388 10.3109/13693786.2011.602126